Agalimmune Ltd., a biopharmaceutical company focused on the development of a pipeline of immunotherapies for the treatment of cancer, has licensed KODE Biotech’s Function-Spacer-Lipid (FSL) cell surface membrane modification technology (KODE Technology). The proprietary technology will be incorporated by Agalimmune into its novel cancer immunotherapy molecules. Under the terms of the agreement, KODE may receive up to $31 million in development and sales milestones, plus royalties on net sales...